Ocular therapeutix™ investor day to highlight exceptional axpaxli™ progress across sol program and detail registrational trial plans to pursue a diabetic retinopathy label with a novel primary endpoint

Sol-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1q 2026

SOL Ratings Summary

SOL Quant Ranking